Complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis

被引：0
|
作者：
Ploumen, R. [1 ,2 ]
Claassens, E. [1 ]
Kooreman, L. [2 ,3 ]
Keymeulen, K. [1 ]
van Kats, M. [4 ]
Gommers, S.
Siesling, S. [6 ,7 ]
van Nijnatten, T. [2 ,5 ]
Smidt, M. [1 ,2 ]
机构：
[1] Maastricht Univ, Surg, Med Ctr, Maastricht, Netherlands
[2] GROW, Sch Oncol & Reprod, Maastricht, Netherlands
[3] Maastricht Univ, Pathol, Med Ctr, Maastricht, Netherlands
[4] Maastricht Univ, Med Oncol, Med Ctr, Maastricht, Netherlands
[5] Maastricht Univ, Radiol & Nucl Med, Med Ctr, Maastricht, Netherlands
[6] Univ Twente, Hlth Technol & Serv Res, Tech Med Ctr, Enschede, Netherlands
[7] Netherlands Comprehens Canc Org, Res & Dev, Utrecht, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 175卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1LBA
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [31] Evaluation of a ductal carcinoma in situ component accompanying HER2-positive invasive breast cancer on contrast-enhanced mammography
    Ploumen, Roxanne A. W.
    Mommertz, Jody A.
    Minis-Rutten, Iris J. G.
    Kooreman, Loes F. S.
    Smidt, Marjolein L.
    van Nijnatten, Thiemo J. A.
    EUROPEAN JOURNAL OF RADIOLOGY, 2025, 186
  • [32] Systemic therapy for metastatic HER2-positive breast cancer
    Bredin, Philip
    Walshe, Janice M.
    Denduluri, Neelima
    SEMINARS IN ONCOLOGY, 2020, 47 (05) : 259 - 269
  • [33] Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast
    Usui, Yuki
    Matsunuma, Ryoichi
    Yamaguchi, Kei
    Hayami, Ryosuke
    Muramatsu, Aya
    Suzuki, Makoto
    Tsuneizumi, Michiko
    CASE REPORTS IN ONCOLOGY, 2021, 14 (03): : 1536 - 1541
  • [34] Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
    Chen, Wei
    Zhang, Jing
    Li, Fenxiang
    Chen, Zongshun
    Li, Junjie
    Lu, Da-Lin
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [35] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [36] Review of the status of neoadjuvant therapy in HER2-positive breast cancer
    Dowling, Gavin P.
    Keelan, Stephen
    Toomey, Sinead
    Daly, Gordon R.
    Hennessy, Bryan T.
    Hill, Arnold D. K.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [37] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    CANCER RESEARCH, 2022, 82 (04)
  • [38] Impact of anthracyclines use on pathological complete response to neoadjuvant treatment in HER2-positive breast cancer
    Teixeira, C.
    Goncalves, M.
    Valente, A. C.
    Reis, J.
    Tavares, N.
    Augusto, I.
    Sousa, I.
    Almeida, D.
    Ribeiro, M. J.
    Barbosa, M.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 32 - 32
  • [39] MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
    Mette S. van Ramshorst
    Claudette E. Loo
    Emilie J. Groen
    Gonneke H. Winter-Warnars
    Jelle Wesseling
    Frederieke van Duijnhoven
    Marie-Jeanne T. Vrancken Peeters
    Gabe S. Sonke
    Breast Cancer Research and Treatment, 2017, 164 : 99 - 106
  • [40] MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
    van Ramshorst, Mette S.
    Loo, Claudette E.
    Groen, Emilie J.
    Winter-Warnars, Gonneke H.
    Wesseling, Jelle
    van Duijnhoven, Frederieke
    Peeters, Marie-Jeanne T. Vrancken
    Sonke, Gabe S.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (01) : 99 - 106
12345